Left Atrial Appendage Closure Devices Market Size By Product (Endocardial LAA Devices, Epicardial LAA Devices), By Procedure (Percutaneous, Surgical), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Applica

Left Atrial Appendage Closure Devices Market Size By Product (Endocardial LAA Devices, Epicardial LAA Devices), By Procedure (Percutaneous, Surgical), By End-use (Hospitals, Ambulatory Surgical Centers), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 - 2032

Global Left Atrial Appendage Closure Devices market is poised to experience a stellar growth through 2032. The growth can be ascribed to a host of novel product innovations and rising government initiatives to increase the awareness for atrial fibrillation among the geriatric population.

In 2022, Abbott Laboratories announced the U.S. availability of its Amplatzer Steerable Delivery Sheath used with Amplatzer Amulet Left Atrial Appendage Occluder to cure patients with AFib. The recent inclusion to Abbott’s portfolio demonstrates the firm’s commitment to innovating across heart ailments, including left atrial appendage closure.

The elevating geriatric population worldwide is also likely to contribute to the growth trajectory of left atrial appendage closure devices industry over 2023-3032. According to the WHO estimates, the number of persons aged 80 years and above is anticipated to triple between 2020 and 2050, reaching 426 million by 2050 end.

Overall, the left atrial appendage closure devices market landscape is bifurcated in terms of products, procedure, end-use, and regions.

On the basis of product, the endocardial LAA closure devices segment is slated to gain considerable returns by 2032. Factors like growing awareness regarding the advantages offered by endocardial LAA devices and the increasing demand in treatment of AFib would support the segmental expansion. In addition, the devices have been recognized to avert the risk of thromboembolic events with acceptable procedure-related complications.

Considering the procedure, the LAA closure devices market share from surgical procedure segment would account for appreciable growth during 2023-2032. The progression is driven by the merits offered by surgical LAA closure devices in LAA closure procedures. The effectiveness of the equipment depends fundamentally on their ability to sustain a high occlusion pressure compared to stapling and suture ligation. Besides, the approach delivers an opportunity to prevent systemic anticoagulation, thus reducing the risk of bleeding.

Based on end-use, hospitals are expected to acquire a substantial business share through 2032 fueled by the mounting use of LAA closure devices in hospital setting for surgical procedures. Presence of highly skilled medical professionals, growing disease screening initiatives, and optimum patient care in hospitals would further propel the segmental expansion.

On the regional purview, Europe left atrial appendage closure devices market would record noteworthy gains between 2023-2032. Elevating elderly population graph in the continent is one of the prominent factors stimulating the regional progression. According to Eurostat statistics, there will be nearly half a million centenarians in the EU-27 by 2050 end.

Moreover, expanding prevalence of AFib in the older population in Europe would contribute to the regional LAA closure devices market growth. The prevalence of atrial fibrillation among individuals older than 55 years is predicted to reach 14 million by 2060, as stated by a recent study.

Some of the prominent companies operating in global left atrial appendage closure devices industry are Abbott Laboratories, Boston Scientific Corporation, Johnson and Johnson, AtriCure, and others. These companies are strategically involved in partnerships, mergers and acquisitions, and product launches to gain a competitive edge in the overall market.